On January 1, 2026 ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage biopharmaceutical company specializing in rare diseases, reported that its leadership team will be in San Francisco during the 43rd Annual J.P. Morgan Healthcare Conference (January 12–15, 2026) to conduct strategic 1-on-1 meetings with global pharmaceutical companies and investors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Instead of a formal stage presentation, ImmunoForge is focusing on high-level private partnering sessions to discuss the clinical progression and licensing of its key pipelines. The company’s primary objective is to secure strategic partners capable of spearheading U.S. clinical trials for its Phase 2 assets.
Key Highlights for Partnering:
Monthly long-acting ELP (Elastin-Like Polypeptide) platform: Peptide conjugation and Protein fusion possible
BBB penetrating ELP (Elastin-Like Polypeptide) platform: BBB shuttle platform fusing ELP to make monthly CNS drugs
PF1801 (Polymyositis/Dermatomyositis, DMD & Sarcopenia): Currently in a Phase 2 study in South Korea. With U.S. FDA Phase 2 IND clearance already secured for both indications, the asset is primed for an immediate U.S. clinical launch by a global partner.
PF1804 (DMD Cardiomyopathy): This promising asset also received FDA Phase 2 IND clearance, standing ready for clinical execution.
PF1807 (Sarcopenia): A monthly sarcopenia therapy based on use patent for the prevention and treatment of myositis and sarcopenia.
KF1601 (CML): While domestic rights have been successfully licensed out ahead of a Phase 1 launch in Korea next year, global licensing rights (excluding Korea) are open for discussion, offering a validated opportunity for international partners.
"Our goal for JPM 2026 week is to meet with potential partners who can leverage our FDA-cleared INDs to rapidly bring these therapies to the U.S. market," said a representative from ImmunoForge. "As a lean biotech, we have focused on de-risking our assets through regulatory clearances; we are now looking for the right global collaborators to take these programs through the next phase of clinical development and to the commercial markets. In addition to licensing deals with global pharmaceutical companies, we are also actively willing to pursue NewCo models led by investors. In line with this strategy, we intend to expand our development capabilities by introducing our diverse pipeline to global companies, including our established long-acting ELP platform and the newly developed BBB-penetrating ELP platform technology."
Schedule for Meeting
ImmunoForge is currently accepting meeting requests for the week of JPM 2026. To schedule a session with our executive team in San Francisco.
(Press release, ImmunoForge, JAN 1, 2026, View Source [SID1234661690])